VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LIVNLivaNova PLC
$83.43$4.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksLIVNFinancials

LivaNova PLC (LIVN) Financials

30Y historyFree accessUpdated daily

Revenue growth has accelerated to 14.3% in 2026Q1, though operating income remains constrained at an 11.5% margin due to elevated SG&A costs.

LIVN Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Apr'15Apr'14Apr'13Apr'12Apr'11Apr'10Apr'09Apr'08Apr'07Apr'06Apr'05Apr'04Apr'03Apr'02Jun'00Jun'99Jun'98Jun'97Jun'96Jun'95
Sales/Revenue1.43B1.39B1.25B1.15B1.02B1.04B934.24M1.08B1.11B1.01B1.21B291.56M282.01M254.32M218.5M190.46M167.78M143.6M121.23M130.97M123.44M103.44M110.72M104.47M70.11M47.89M29.9M14.9M1.4M1.4M1M
Revenue Growth %12.4%10.74%8.66%12.89%-1.31%10.82%-13.83%-2.06%9.35%-16.61%316.35%3.38%10.89%16.39%14.72%13.52%16.83%18.45%-7.44%6.1%19.33%-6.57%5.99%49%46.4%60.16%100.67%964.29%0%40%150%
Cost of Goods Sold466.12M448.2M382.56M382.3M314.58M329.37M339.48M360.37M372.5M360.7M509.5M27.31M27.35M21.91M19.66M23.02M20.91M20.04M21.09M18.26M15.82M15.58M16.3M16.07M13.62M10.38M6.2M3.2M100K200K0
COGS % of Revenue-32.29%30.52%33.14%30.79%31.81%36.34%33.24%33.65%35.63%41.97%9.37%9.7%8.61%9%12.09%12.46%13.96%17.4%13.94%12.82%15.06%14.72%15.38%19.42%21.68%20.74%21.48%7.14%14.29%-
Gross Profit967.36M939.9M870.87M771.25M707.23M705.99M594.76M723.8M734.5M651.6M704.4M264.25M254.66M232.41M198.85M167.44M146.87M123.56M100.14M112.71M107.62M87.87M94.43M88.4M56.49M37.5M23.7M11.7M1.3M1.2M1M
Gross Margin %67.48%67.71%69.48%66.86%69.21%68.19%63.66%66.76%66.35%64.37%58.03%90.63%90.3%91.39%91%87.91%87.54%86.04%82.6%86.06%87.18%84.94%85.28%84.62%80.58%78.32%79.26%78.52%92.86%85.71%100%
Gross Profit Growth %-7.93%12.92%9.05%0.17%18.7%-17.83%-1.46%12.72%-7.5%166.57%3.77%9.57%16.88%18.75%14.01%18.86%23.39%-11.15%4.73%22.48%-6.95%6.82%56.48%50.63%58.25%102.56%800%8.33%20%66.67%
Operating Expenses775.16M740.5M741.82M839.75M783.98M706.78M868.66M895.36M648.2M523.4M637.2M166.9M167.2M154.07M137.9M118.26M110.01M104.57M108.37M162.24M166.85M100.77M87.73M83.72M83.71M42.76M37.8M27.9M12.7M11.6M8.9M
OpEx % of Revenue-53.35%59.18%72.8%76.72%68.26%92.98%82.58%58.55%51.7%52.49%57.25%59.29%60.58%63.11%62.09%65.57%72.82%89.39%123.87%135.17%97.42%79.24%80.14%119.39%89.28%126.42%187.25%907.14%828.57%890%
Selling, General & Admin563.25M548.8M526.26M518.13M469.24M471.9M00465M380.6M469.2M123.62M120.64M112.52M102.57M89.65M87.94M84.84M85.94M134.14M137.31M81.43M70.6M65.84M59.19M33.27M29.6M19.8M5.9M3.4M8.6M
SG&A % of Revenue-39.54%41.99%44.92%45.92%45.58%--42.01%37.6%38.65%42.4%42.78%44.24%46.94%47.07%52.42%59.08%70.89%102.42%111.23%78.72%63.76%63.03%84.42%69.47%99%132.89%421.43%242.86%860%
Research & Development206.56M185.8M182.51M193.82M155.81M183.41M152.9M197.15M146M109.7M122.5M43.28M46.56M41.55M35.33M28.6M22.06M19.73M22.42M28.09M29.54M19.34M17.13M17.87M24.52M8.04M6.7M7.4M6.5M8M0
R&D % of Revenue-13.39%14.56%16.8%15.25%17.71%16.37%18.18%13.19%10.84%10.09%14.85%16.51%16.34%16.17%15.02%13.15%13.74%18.49%21.45%23.93%18.7%15.47%17.11%34.97%16.78%22.41%49.66%464.29%571.43%-
Other Operating Expenses1.84M5.9M33.04M127.8M158.93M51.46M715.76M698.21M37.19M33.14M45.51M642.36K-295.27K000000000006001.45M1.5M700K300K200K300K
Operating Income192.3M199.4M129.05M-68.5M-76.75M-784K-273.9M-171.55M-248.1M95.7M-27.6M88.65M80.01M78.35M60.94M49.19M36.86M18.99M-8.23M-49.53M-59.23M-12.91M6.7M4.68M-27.21M-5.25M-14.1M-16.2M-11.4M-10.4M-7.9M
Operating Margin %13.41%14.37%10.3%-5.94%-7.51%-0.08%-29.32%-15.82%-22.41%9.45%-2.27%30.41%28.37%30.81%27.89%25.83%21.97%13.22%-6.79%-37.82%-47.98%-12.48%6.05%4.48%-38.81%-10.97%-47.16%-108.72%-814.29%-742.86%-790%
Operating Income Growth %-54.51%288.4%10.75%-9689.8%99.71%-59.66%30.85%-359.25%446.74%-131.13%10.8%2.13%28.56%23.9%33.44%94.12%330.77%83.39%16.39%-358.98%-292.76%42.95%117.21%-418.23%62.76%12.96%-42.11%-9.62%-31.65%-21.54%
EBITDA219.63M241.4M180.19M-7.64M-18.96M67.2M-206.56M-100.86M-178.16M165.9M35.96M95.91M85.61M82.98M65.67M51.93M39.09M21.17M-4.27M-45.04M-54.74M-8.92M11.61M9.8M-22.92M-3.8M-12.6M-15.5M-11.1M-10.2M-7.6M
EBITDA Margin %15.32%17.39%14.38%-0.66%-1.86%6.49%-22.11%-9.3%-16.09%16.39%2.96%32.89%30.36%32.63%30.06%27.26%23.3%14.74%-3.52%-34.39%-44.35%-8.62%10.49%9.38%-32.69%-7.94%-42.14%-104.03%-792.86%-728.57%-760%
EBITDA Growth %2.58%33.97%2457.96%59.69%-128.21%132.54%-104.79%43.39%-207.39%361.3%-62.5%12.02%3.17%26.36%26.47%32.83%84.65%595.85%90.52%17.73%-513.83%-176.8%18.45%142.77%-502.93%69.83%18.71%-39.64%-8.82%-34.21%-22.58%
D&A (Non-Cash Add-back)27.33M42M51.14M60.86M57.8M67.99M67.34M70.69M69.94M70.2M63.56M7.25M5.6M4.64M4.73M2.74M2.23M2.18M3.96M4.49M4.49M3.99M4.92M5.12M4.29M1.45M1.5M700K300K200K300K
EBIT179.3M-171.5M151.38M-22.37M-26.89M-74.32M-60.99M48.49M-237.62M128.94M35.82M-56.66M89.31M79.9M75.39M60.72M49.06M39.92M30.84M-8.23M-49.53M-59.23M-19.3M4.55M4.68M-5.25M-5.25M-14.1M-16.2M-11.4M-10.4M
Net Interest Income-20.1M-49.3M-32.99M-36.84M-43.55M-49.72M-40.71M-14.29M-8.98M-6.48M-8.92M0163K162K-35K29.39K-135.68K-1.34M-2.16M-1.97M-1.26M192.99K628.22K-95.78K998.58K000000
Interest Income14.53M030.07M22.01M4.7M435K131K803K847K1.32M1.7M0182.27K182K84K326.12K92.6K1.24M3.84M4.65M3.21M1.07M469.92K469.92K1.26M000000
Interest Expense34.63M49.3M63.07M58.85M48.25M50.15M40.84M15.09M9.82M7.8M10.62M162.89K20.05K20K119K296.73K1.43M3.39M5.82M5.91M3.02M444.27K565.7K565.7K266.27K44.89K00000
Other Income/Expense-69.93M-420.2M-40.74M-12.83M1.56M-123.84M-74.39M43.92M625K24.65M-66.45M-130.98M642K-133K-3.07M-521.42K-522.71K1.63M8.46M-2.37M-1.57M262.45K712.95K-1.85M93.69K-44.89K5.25M2M5M1.3M3.2M
Pretax Income122.37M-220.8M88.31M-81.33M-75.19M-124.62M-348.29M-127.63M-247.4M121.1M-33M89.29M79.88M75.27M60.42M48.66M38.49M27.45M-10.6M-51.1M-58.97M-12.19M6.99M5.31M-27.12M-5.3M-14M-14.2M-11.2M-10.1M-7.2M
Pretax Margin %8.54%-15.91%7.05%-7.05%-7.36%-12.04%-37.28%-11.77%-22.35%11.96%-2.72%30.63%28.32%29.6%27.65%25.55%22.94%19.12%-8.74%-39.02%-47.77%-11.79%6.31%5.09%-38.68%-11.06%-46.82%-95.3%-800%-721.43%-720%
Income Tax14.4M21.6M25.06M-98.88M11.05M11.2M-960K-30.37M-69.63M49.95M5.11M31.45M31.45M24.99M28.92M24.34M1.94M-39.96M729.44K-264.84K78.78K99.27K26.11K230.79K129.56K-2.15M00000
Effective Tax Rate %11.77%-9.78%28.38%121.57%-14.7%-8.99%0.28%23.8%28.14%41.25%-15.49%35.22%39.37%33.2%47.86%50.02%5.04%-145.57%-6.88%0.52%-0.13%-0.81%0.37%4.34%-0.48%40.65%0%0%0%0%0%
Net Income107.14M-242.5M63.23M17.55M-86.25M-135.82M-348.82M-157.64M-189.4M-25.1M-62.8M57.85M54.89M46.36M36.08M46.73M78.45M26.72M-10.33M-51.18M-59.07M-12.22M6.76M5.18M-26.12M-3.05M-12.5M-14.2M-11.2M-10.1M-7.2M
Net Margin %7.47%-17.47%5.04%1.52%-8.44%-13.12%-37.34%-14.54%-17.11%-2.48%-5.17%19.84%19.46%18.23%16.51%24.53%46.76%18.61%-8.52%-39.08%-47.85%-11.81%6.11%4.96%-37.25%-6.38%-41.81%-95.3%-800%-721.43%-720%
Net Income Growth %148.23%-483.5%260.39%120.34%36.5%61.06%-121.28%16.77%-654.58%60.03%-208.56%5.39%18.41%28.49%-22.79%-40.44%193.59%358.55%79.81%13.36%-383.45%-280.76%30.37%119.85%-755.48%75.57%11.97%-26.79%-10.89%-40.28%-22.03%
Net Income (Continuing)107.12M-242.5M63.25M17.55M-86.25M-135.82M-347.33M-158M-177.82M71.18M20.55M-22.08M57.85M54.89M46.36M36.08M46.73M78.45M26.72M-10.33M-51.18M-59.07M-18.61M4.62M5.18M-3.05M-3.93M-12.5M-14.2M-11.2M-10.1M
Discontinued Operations000000-1.49M365K0-79.55M-64.66M-22.34M0000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)1.92-4.451.160.32-1.61-2.68-7.06-3.22-3.91-0.52-1.282.172.001.661.271.632.730.97-0.39-2.01-2.37-0.510.260.24-1.21-0.17-0.71-0.88-0.93-1.06-0.79
EPS Growth %147.92%-483.62%262.5%119.88%39.93%62.04%-119.25%17.65%-651.92%59.38%-158.99%8.5%20.48%30.71%-22.09%-40.29%181.44%348.72%80.6%15.19%-364.71%-296.15%8.33%119.83%-611.76%76.06%19.32%5.38%12.26%-34.18%-19.7%
EPS (Basic)--4.451.170.33-1.61-2.68-7.06-3.22-3.91-0.52-1.292.192.021.681.301.672.831.00-0.39-2.01-2.37-0.510.290.24-1.21-0.17-0.71-0.88-0.93-1.06-0.79
Diluted Shares Outstanding55.9M54.5M54.57M54.21M53.5M50.63M48.59M48.35M48.5M48.5M48.9M26.63M27.47M28.01M28.31M28.61M28.7M27.54M26.5M25.51M24.92M24.04M25.66M22.03M21.66M18.04M17.5M16.1M12.04M9.51M9.11M
Basic Shares Outstanding54.7M54.5M54.24M53.9M53.5M50.63M48.59M48.35M48.5M48.2M48.86M26.39M27.14M27.6M27.83M28.05M27.7M26.63M26.5M25.51M24.92M24.04M23.09M22.03M21.66M18.04M17.5M16.1M12.04M9.51M9.11M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetMixed
Cash FlowImproving
Top Statement Risk

Legacy litigation and impairments

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Momentum Reflects Segment Scaling

According to the most recent quarterly filings, LivaNova achieved a 14.3% year-over-year revenue growth rate in 2026Q1, marking a notable acceleration from the 3.8% growth observed in 2024Q4, suggesting that the company's strategic focus on high-growth neuromodulation and cardiopulmonary platform adoption is beginning to yield tangible top-line results.

The consistent upward trend in quarterly revenue, moving from $294.9 million in 2024Q1 to $362.3 million in 2026Q1, indicates that the company is successfully navigating its transition toward higher-value product lines. Investors should monitor whether this growth is sustainable or if it remains heavily dependent on the timing of capital equipment cycles within the cardiopulmonary segment.

Gross Margin Stability Amid Volatility

As reported in financial statements, LivaNova maintained a gross margin of 67.3% in 2026Q1, which, while slightly below the historical peak of 70.8% seen in 2024Q3, demonstrates a resilient pricing power for its specialized medical device portfolio despite ongoing supply chain and inflationary pressures on input costs.

The ability to sustain gross margins near the 67-70% range suggests that the company's core VNS and cardiopulmonary disposables retain significant competitive moats. However, the periodic fluctuations in these margins warrant further investigation into whether they stem from product mix shifts or temporary inefficiencies in manufacturing overhead.

Operating Leverage Remains Under Pressure

Based on reported figures, operating income reached $41.5 million in 2026Q1, representing an 11.5% margin, which highlights a persistent struggle to scale operating expenses efficiently as SG&A costs continue to consume a substantial portion of the gross profit generated by the company's primary business segments.

The lack of significant operating margin expansion despite top-line growth suggests that the company is heavily reinvesting in its sales force and regulatory infrastructure. Analysts should scrutinize whether these elevated SG&A levels are necessary for long-term market penetration or if they reflect a lack of discipline in managing overhead costs.

Net Income Distorted by Non-Operating Items

Data from the income statement reveals that net income has been highly volatile, swinging from a $327.3 million loss in 2025Q1 to a $22.3 million profit in 2026Q1, which appears to be driven by significant non-operating charges rather than core operational performance fluctuations.

The extreme variance in net income suggests that legacy litigation and one-time asset impairments continue to obscure the underlying earnings power of the business. Investors should prioritize adjusted EBITDA metrics to better understand the true cash-generating capability of the firm, as GAAP net income remains an unreliable indicator of current operational health.

LIVN — Frequently Asked Questions

Quick answers to the most common questions about buying LIVN stock.

What was LivaNova PLC's (LIVN) revenue in 2025?

For fiscal year 2025, LivaNova PLC (LIVN) reported total revenue of $1.39B. This represents a 138710.0% increase compared to $1.0M in 1995.

Is LivaNova PLC (LIVN) profitable?

LivaNova PLC (LIVN) reported a net loss of $242.5M for the fiscal year ending 2025.

What is LivaNova PLC's operating profit margin?

LivaNova PLC (LIVN) reported an operating income of $199.4M, resulting in an operating profit margin of 14.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is LivaNova PLC's gross profit and gross margin?

LivaNova PLC (LIVN) generated $939.9M in gross profit for the year, representing a gross profit margin of 67.7%. This demonstrates the company's core pricing power and production efficiency.